Q1 2025 saw Hoodin launch new AI-driven compliance features, secure a major pharma client, and maintain strong equity despite lower revenue and ongoing losses. Strategic partnerships and a proposed rights issue aim to support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.